
About Evelo Biosciences
Evelo Biosciences is a publicly listed company based in Cambridge (United States) founded in 2015. Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. Evelo Biosciences has raised $166.5 million across 4 funding rounds from investors including Flagship Pioneering, Celgene and Google Ventures. Evelo Biosciences has completed 1 acquisition, including Epiva Therapeutics. Its chief executive, as recorded, is Simba Gill. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is EVELO BIOSCIENCES, INC. Its competitors include Ironwood Pharma, Alcresta and Seed; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.
- Headquarters Cambridge, United States
- Stage Public
- SectorsHealthcare
- Website evelobio.com
- Social LinkedIn X
- Legal Name Evelo Biosciences, Inc.
- Net Profit-$114.53 M (USD)6.26as on Dec 31, 2022
- EBITDA-$103.51 M (USD)7.03as on Dec 31, 2022
- Total Equity Funding$166.5M (USD)
in 4 rounds
- Latest Funding Round$25.5M (USD), Post-IPO
Jul 2023
- InvestorsFlagship Pioneering
& 4 more
- Investments & Acquisitions
Funding Insights of Evelo Biosciences
Evelo Biosciences has successfully raised a total of $166.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.5 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $166.5M
- Total Rounds 4
- Last Round Post-IPO β $25.5M
- First Round $35M
(Nov 2015)
- Investors Count 5
All 4 funding rounds of Evelo Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $25.5M | Post-IPO | β | β | |
| Mar 2018 | $81.5M | Series C | β | β | β |
| Jul 2017 | $50M | Series B | β | Flagship Pioneering, Google Ventures | β |
| Nov 2015 | $35M | Series A | β | β |
5 investors in total: 5 institutional.
Investors in Evelo Biosciences
Evelo Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Flagship Pioneering, Celgene and Google Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Early stage investments focused VC firm | acks.com | |||
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
| ventures.mayoclinic.org |
Investor details for Evelo Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evelo Biosciences
20 people are tracked at Evelo Biosciences (6 in leadership, 7 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Simba Gill | CEO | Leadership |
Andrea Itano | Head, Research | Leadership |
Aylwin Ng | Head of Systems Immunology | Leadership |
Jonathan Zhung | Chief Development Officer | Leadership |
Daniela Walker | Clinical Operations Lead/associate Director | Leadership |
Maria Sizova | Senior Director Microbiology | Leadership |
Juan Andres | Director | Board & advisors |
Theodose Melas-Kyriazi | Director | Board & advisors |
Tonya Williams | Director | Board & advisors |
Robert L. Rosiello | Chairman | Board & advisors |
Alexander C. Reynolds | Director | Board & advisors |
Jeffrey R. Moore | Director | Board & advisors |
Jose-Carlos Gutiérrez-Ramos | Director | Board & advisors |
Laura Jackson | Scientist | Team |
Amrita Bhattacharjee | Senior Scientist | Team |
Janae Peel | Data Entry Clerk | Team |
Anthony Mannion, Ph.D. | Senior Scientist | Team |
Lhakyi L. | Laboratory Operations Coordinator | Team |
Barbara J. Romano | Development Operations | Team |
Brianna MacDonald | Senior Accountant | Team |
Complete people profiles for Evelo Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Evelo Biosciences
Evelo Biosciences is a publicly listed company on the OTC with ticker symbol EVLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 May 2018
- Listed onNASDAQ: NASDAQ
- Listed entityEvelo Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS2997342025
- Share price$0.00 · 2026-10-06
- Market capitalisation$3,796.56
- Volume (last session)370
Financials of Evelo Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | -$114.5M | -$103.5M | |
| 2021 | -$122.2M | -$111.3M | |
| 2020 | -$93.7M | -$87.9M |
Detailed financial statements for Evelo Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evelo Biosciences
Evelo Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epiva Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Microbiome-based therapeutics are developed for autoimmune diseases. | epiva.com | Cambridge, United States | 2015 | Jul 2016 | β’β’β’β’ |
Complete acquisition details for Evelo Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Evelo Biosciences
5 dated milestones of Evelo Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Evelo Biosciences is founded.
- Funding First funding round of $35.0M.
- Acquisition Acquires Epiva Therapeutics.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.5M.
Competitors of Evelo Biosciences
Evelo Biosciences has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Alcresta and Seed.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | Synbiotics are developed for simulating the gut microbiome. |
Detailed competitors of Evelo Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Evelo Biosciences (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evelo Biosciences
Complete news archive for Evelo Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evelo Biosciences
Evelo Biosciences was founded in 2015.
Evelo Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Simba Gill is the CEO of Evelo Biosciences, as recorded in our data.
Evelo Biosciences is a funded company, having raised a total of $166.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on Nov 2015.
Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.
Evelo Biosciences's top competitors include Ironwood Pharma, Seed and Alcresta.
Yes, Evelo Biosciences is publicly traded on OTC under the ticker symbol EVLO.
Evelo Biosciences has made 1 acquisition, including Epiva Therapeutics.
Evelo Biosciences has 5 investors. Key investors include Flagship Pioneering, Celgene, Google Ventures, Acks, and Mayo Clinic Ventures.
Evelo Biosciences operates through Evelo Biosciences, Inc..
